NCT01121354 - Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Infection

Interventions

DRUG

Cefazolin 2g for Injection USP and Dextrose Injection USP

Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.

DRUG

Cefazolin 1.5g

Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.

Trial Locations (1)

21225

PAREXEL Early Phase Clinical Unit, Baltimore